Eli Lilly will invest over $1 billion in India over the coming years to expand its contract manufacturing capabilities, the U.S. pharmaceutical company announced on Monday. The investment aims to improve global access to treatments for obesity, diabetes, Alzheimer's disease, cancer, and autoimmune disorders.
The company will establish a manufacturing and quality facility in Hyderabad to provide technical oversight for its contract manufacturing operations throughout India. Lilly will begin hiring engineers, chemists, analytical scientists, quality professionals, and managers to support the expansion.
Nivruti Rai, managing director of Invest India under the Ministry of Commerce and Industry, said the investment demonstrates confidence...